Deepnoid and Indonesia hospital collaborate on medical AI clinical study

Deepnoid, a Korean medical AI company, said Thursday that it has signed an MOU with Universitas Gadjah Mada (UGM) Academic Hospital in Indonesia for clinical research.

Under the agreement, UGM Academic Hospital will conduct clinical research using Deepnoid's artificial intelligence solutions, including “DEEP:CHEST,” a real-time multi-lung disease detection and diagnosis aid, “DEEP:LUNG,” a real-time lung nodule detection and diagnosis aid, and “DEEP:NEURO,” a brain aneurysm diagnosis aid, for 18 months.

Based on the clinical trial results, Deepnoid plans to apply for a medical device license in Indonesia.

UGM Academic Hospital in Yogyakarta, Indonesia, is part of a council that supports seven national university hospitals in two provinces. The group includes 10 other medical institutions. With major healthcare organizations on board, Deepnoid expects more MOUs and demo installations.

According to Deepnoid, the number of X-ray, MRI, and CT readings at the UGM Academic Hospital has increased by 140.8 percent in the last three years, but the number of readers is only 22. The number of patients covered by public insurance is also increasing at a high rate every year, and the need for imaging is expected to grow further.

"This agreement is significant as we are entering the Indonesian market in earnest," Deepnoid CEO Choi Woo-sik said. "We will spare no effort to ensure that patients at UGM Academic Hospital receive fast and accurate reading results and that our AI reading solution is fully established in the Indonesian healthcare market."